Skip to content
Search

Latest Stories

Invatech Health sells its care homes electronic medication administration system to PCS

Health technology pioneer Invatech Health has sold its care homes electronic medication administration record (eMAR) system Atlas to care home management specialists Person Centred Software (PCS).

Following the transition of Atlas to new ownership, Bristol-based Invatech Health will concentrate solely on further growth of Titan, its cutting-edge software for pharmacy management.


Invatech Health CEO Tariq Muhammad, a pharmacist who started working on care homes back in 2002, first conceived the concept of electronic medicines system for care homes in 2006.

Muhammad said he was proud to see his purpose-driven business given an opportunity for further progress. “It’s a bit like being at a child’s graduation,” he said, after the completion of the acquisition which marked the end of a 20 year journey for him with Atlas.

“I set up Atlas to tackle a dire need in the care homes sector for a system which could prevent incorrect dosing, mismanagement of prescriptions and administration errors of important medication.

“For me Atlas has always been about the end user – care homes and their residents. It’s taken a long time to perfect it and, as with any business, there have been bumps along the way.

"Now I’ve taken Atlas as far as I can, so I’m delighted to see it under new ownership, with a company whose values I share and who can allow it to reach greater heights as part of a new ecosystem.

“It’s a clean acquisition, with a complete continuation in staffing and functionality, so it couldn’t have happened any better for all involved.

“My management team and I will oversee the transition over coming months to ensure Atlas is properly bedded in. We can then focus all our efforts into the exciting development of Titan – a similarly cutting-edge product and the equivalent in the rapidly-growing pharmacy sector.

“The potential for Titan is massive. So while I’ve seen one brainchild flying the nest today, there’s another one growing rapidly which needs our full attention.”

PCS, which is based in Guildford in Surrey, confirmed that as part of the acquisition it would retain Atlas’s full team of 15 staff, all of whom work remotely.

Atlas is currently deployed in 700 care homes across the UK, and serviced by a 165-strong network of independent pharmacies, now has the opportunity to be further implemented across PCS’s client base of 3,000 care homes in total.

Jonathan Papworth, co-founder of PCS, said: “I have been impressed with the proven capabilities built into Atlas, alongside the unique level of integration across GPs and pharmacies.

“Atlas is joining our family of social care products to provide best-in-class clinical software for our global customers, from digital care records to medication management and beyond.

“This will provide our joint customers with the opportunity to have full interoperability across our products, as well as the most comprehensive and capable integration with healthcare systems.”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less